Prognostic significance of E-cadherin and N-cadherin expression in Gliomas

• Published in: BMC cancer Vol. 17; no. 1; p. 583
• Main Authors: Noh, Myung-Giun, Oh, Se-Jeong, Ahn, Eun-Jung, Kim, Yeong-Jin, Jung, Tae-Young, Jung, Shin, Kim, Kyung-Keun, Lee, Jae-Hyuk, Lee, Kyung-Hwa, Moon, Kyung-Sub
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29-08-2017; BioMed Central; BMC
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD - metabolism; Biomarkers, Tumor - metabolism; Brain cancer; Brain tumors; Breast cancer; Cadherins; Cadherins - metabolism; Cancer metastasis; Cell Line, Tumor; Child; Child, Preschool; Development and progression; Diagnosis; Disease-Free Survival; E-cadherin; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Glioma; Glioma - metabolism; Glioma - pathology; Glioma cells; Gliomas; Humans; Immunoglobulins; Invasiveness; Kaplan-Meier Estimate; Male; Mesenchyme; Metastases; Metastasis; Middle Aged; N-Cadherin; Neoplasm Grading; Nervous system; NMR; Nuclear magnetic resonance; Patients; Prognosis; Stem cells; Survival; Tissue Array Analysis; Tumors; Young Adult; Epithelial-mesenchymal transition; Prognosis; Glioma; N-cadherin; E-cadherin; Survival
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-017-3591-z

Epithelial-mesenchymal transition (EMT), principally involving an E-cadherin to N-cadherin shift, linked to tumor invasion or metastasis, and therapeutic resistance in various human cancer. A growing body of recent evidence has supported the hypothesis that EMT play a crucial role in the invasive phenotype of gliomas. To evaluate the prognostic connotation of EMT traits in glioma, expression of E-cadherin and N-cadherin was explored in a large series of glioma patients in relation to patient survival rate.
Expressions of E- and N-cadherin were examined using immunohistochemical analysis in 92 glioma cases diagnosed at our hospital. These markers expressions were also explored in 21 cases of fresh frozen glioma samples and in glioma cell lines by Western blot analysis.
Expression of E-cadherin was observed in eight cases (8.7%) with weak staining intensity in the majority of the immunoreactive cases (7/8). Expression of N-cadherin was identified in 81 cases (88.0%) with high expression in 64 cases (69.5%). Fresh frozen tissue samples and glioma cell lines showed similar results by Western blot analysis. There was no significant difference in either overall survival (OS) or progression-free survival (PFS) according to E-cadherin expression (P > 0.05). Although the OS rates were not affected by N-cadherin expression levels (P = 0.138), PFS increased in the low N-cadherin expression group with marginal significance (P = 0.058). The survival gains based on N-cadherin expression levels were significantly augmented in a larger series of publicly available REMBRANDT data (P < 0.001).
E- and N-cadherin, as representative EMT markers, have limited prognostic value in glioma. Nonetheless, the EMT process in gliomas may be compounded by enhanced N-cadherin expression supported by unfavorable prognostic outcomes.